Healthy donors needed to boost Infection-Fighting cells for vulnerable patients
NCT ID NCT01553214
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 5 times
Summary
This study aims to improve the collection of granulocytes (a type of white blood cell) from healthy volunteers. Donors receive filgrastim and dexamethasone to move these cells into the bloodstream, then donate via apheresis. Up to 1,000 donors aged 18-75 can donate up to 12 times per year. The goal is to build a reliable donor registry to meet patient needs at the NIH Clinical Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- filgrastim and dexamethasone
- What this could lead to
- If successful, this could create a reliable donor program to provide granulocyte transfusions for patients with weakened immune systems, helping them fight infections.
- What could go wrong
- This is a Phase 4 study focused on donor feasibility, not treatment outcomes. Long-term effects of repeated filgrastim and dexamethasone in donors are still being monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC GRANULOCYTE DONATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States